Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer

This publication has 69 references indexed in Scilit:

• Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
  Cancer Research, 2011
• Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
• Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis
  Journal of Experimental Medicine, 2010
• Biomarkers of response and resistance to antiangiogenic therapy
  Nature Reviews Clinical Oncology, 2009
• The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings
  Cell Proliferation, 2009
• G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
  Proceedings of the National Academy of Sciences, 2009
• TGFβ in Cancer
  Cell, 2008
• Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
  Molecular Cell, 2008
• Molecular and cellular biomarkers for angiogenesis in clinical oncology
  Drug Discovery Today, 2007
• The Peptidyl Prolyl cis/trans Isomerase FKBP38 Determines Hypoxia-Inducible Transcription Factor Prolyl-4-Hydroxylase PHD2 Protein Stability
  Molecular and Cellular Biology, 2007